Trastuzumab and Hyaluronidase-Oysk
Brand Names: Herceptin Hylecta
Methodology & AI Transparency ⓘ
Trastuzumab and Hyaluronidase-Oysk Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Trastuzumab and Hyaluronidase-Oysk is an FDA-registered prescription endoglycosidase (subcutaneous-route administration) manufactured/labeled by Genentech, Inc.
- 2 Real-world patient consensus: Tracked across 8 patient dosage logs with a 86% satisfaction benchmark (RxCUI RXN-50242077-2347).
- 3 Typical cash cost range: Dispensing cost comparison spans $70.06 mail/discount cash up to $171.65 uninsured retail (federal NADAC $1.5200).
- 4 Top reported side effects / signs: Most commonly reported Trastuzumab and Hyaluronidase-Oysk tolerability events: nausea (8.6%), headache (7.1%), dizziness (6.2%).
Ask our AI Specialists anything about Trastuzumab and Hyaluronidase-Oysk
Trastuzumab and Hyaluronidase-Oysk Mechanism, CYP450 Pathways & DailyMed Monograph
Trastuzumab and Hyaluronidase-Oysk is an FDA-registered prescription endoglycosidase (subcutaneous-route administration) manufactured/labeled by Genentech, Inc. under National Drug Code 50242-077, supplied in 600 mg/5mL / 10000 U/5mL Injection, Solution for physician-directed therapeutic management.
Pharmacologically, Trastuzumab and Hyaluronidase-Oysk functions within the Endoglycosidase class via subcutaneous-route delivery (600 mg/5mL / 10000 U/5mL Injection, Solution), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 50242-077 (manufactured/labeled by Genentech, Inc.).
Systemic exposure to Trastuzumab and Hyaluronidase-Oysk reflects Complete (~100%) parenteral systemic delivery for Trastuzumab and Hyaluronidase-Oysk (600 mg/5mL / 10000 U/5mL Injection, Solution) absorption kinetics and phase i/ii hepatic conjugation of trastuzumab and hyaluronidase-oysk coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 6–17 hours terminal plasma half-life for Trastuzumab and Hyaluronidase-Oysk half-life window (rapid intravascular/parenteral onset within 15–45 minutes after trastuzumab and hyaluronidase-oysk administration response profile).
Dosing protocols (600 mg/5mL / 10000 U/5mL Injection, Solution or 600 mg/5mL or 5mL) balance efficacy (86.00% patient satisfaction across 8 logs) against nausea (8.6% of reports), headache (7.1% of reports), dizziness (6.2% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving trastuzumab and hyaluronidase-oysk (endoglycosidase); concurrent restricted medications flagged in section 4/7 of the trastuzumab and hyaluronidase-oysk dailymed monograph (rxn-50242077-2347).
Assess baseline hepatic panels and interacting prescriptions when starting Trastuzumab and Hyaluronidase-Oysk (endoglycosidase).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Trastuzumab and Hyaluronidase-Oysk dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Trastuzumab and Hyaluronidase-Oysk (endoglycosidase)
- Concurrent restricted medications flagged in Section 4/7 of the Trastuzumab and Hyaluronidase-Oysk DailyMed monograph (RXN-50242077-2347)
Logged Side-Effect Incidence (8 Reports)
Trastuzumab and Hyaluronidase-Oysk Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Trastuzumab and Hyaluronidase-Oysk)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and: What a 4,804-Participant Study Found Pertuzumab improved IDFS in all subgroups, with the greatest improvement in HER2 FISH-low/estrogen receptor-positive tumors. Journal of the National Cancer Institute • 2026-08-01 • Phase III Randomized Trial | N = 4,804 | 96/100 | PMID 41934626 ↗ |
| New Insights on Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone: What a 1,862-Participant Study Found The CTS5 model does not accurately predict the risk of late recurrence in HR+, HER2+ BC treated with adjuvant trastuzumab in the N9831 and B-31 trials. Journal of the National Comprehensive Cancer Network : JNCCN • 2024-08-26 • Phase III Randomized Trial | N = 1,862 | 90/100 | PMID 39191270 ↗ |
| New Insights on STAT3 activation in HER2-positive breast cancers: Analysis of data from a large: What a 5,694-Participant Study Found This effect was limited to ER-positive tumors. International journal of cancer • 2021-03-15 • Phase III Randomized Trial | N = 5,694 | 90/100 | PMID 33152119 ↗ |
| Can This Approach Help? Inside the Latest Research on Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted In patients with HER2-positive early BC treated with modern anticancer therapies, young age did not demonstrate either prognostic or predictive value, irrespective of hormone receptor status. Journal of the National Cancer Institute • 2022-08-08 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35512402 ↗ |
| New Insights on Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously: What a 243-Participant Study Found The PUFFIN final analysis showed, per the primary analysis, that overall efficacy of pertuzumab plus trastuzumab and docetaxel was consistent with CLEOPATRA. Breast cancer research and treatment • 2023-02-15 • Phase III Randomized Trial | N = 243 | 88/100 | PMID 36463547 ↗ |
Trastuzumab and Hyaluronidase-Oysk Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.5200/unit (~$45.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $171.65 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $70.06 / mo | View logs ↓ |
Trastuzumab and Hyaluronidase-Oysk Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Trastuzumab and Hyaluronidase-Oysk RxNorm Concept ID | RXN-50242077-2347 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.5200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $171.65 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $70.06 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Trastuzumab and Hyaluronidase-Oysk Patient Community, Cohort Filters & Dosage Logs
Cross-verified Trastuzumab and Hyaluronidase-Oysk (endoglycosidase) monograph synthesizing RxNorm RXN-50242077-2347, openFDA FAERS signals, and $70.06–$171.65 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Trastuzumab and Hyaluronidase-Oysk community threads and patient logs by age, biological sex, dosage, and treatment duration.